Your browser doesn't support javascript.
loading
Life and disease status of patients with Parkinson's disease during and after zero-COVID in China: an online survey.
Huang, Pei; Tan, Yu-Yan; Chen, Biao; Shang, Hui-Fang; Wang, Li-Juan; Liu, Chun-Feng; Chen, Ling; Chang, Ying; Wang, Han; Wang, Xue-Lian; Lei, Xiao-Guang; Yao, Li-Fen; Yu, Yang; Ye, Zheng; Chen, Hai-Bo; Chen, Sheng-Di.
Afiliación
  • Huang P; Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
  • Tan YY; Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
  • Chen B; Department of Neurology, Xuan Wu Hospital Affiliated to Capital Medical University, Beijing, 100053, China.
  • Shang HF; Department of Neurology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Wang LJ; Department of Neurology, Guangdong General Hospital, Guangzhou, 510080, China.
  • Liu CF; Department of Neurology, Suzhou Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
  • Chen L; Department of Neurology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
  • Chang Y; Department of Neurology, China-Japan Union Hospital, Jilin University, Changchun, 130031, China.
  • Wang H; Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
  • Wang XL; Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Lei XG; Department of Neurology, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
  • Yao LF; Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
  • Yu Y; Department of Neurology, Tianjin Huanhu Hospital, Tianjin, 300350, China.
  • Ye Z; Institute of Neuroscience, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, 200031, China.
  • Chen HB; Department of Neurology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, China. chenhbneuro@263.net.
  • Chen SD; Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. chensd@rjh.com.cn.
Transl Neurodegener ; 13(1): 8, 2024 02 06.
Article en En | MEDLINE | ID: mdl-38317265
ABSTRACT

BACKGROUND:

Little is known about the impact of the COVID-19 pandemic on patients with Parkinson's disease (PD) at different stages of the pandemic. This study aims to assess the lives and disease status of PD patients during the zero-COVID policy period and after ending the zero-COVID policy.

METHODS:

This multicenter cross-sectional study included two online surveys among PD patients in China, from May 30 to June 30 in 2022 and from January 1 to February 28 in 2023, respectively. The survey questionnaires contained four sections (1) status of COVID-19 infection; (2) impact on motor and non-motor symptoms; (3) impact on daily and social lives; and (4) impact on PD disease management.

RESULTS:

A total of 1764 PD patients participated in the first online survey, with 200 patients having lockdown experience and 3 being COVID-19-positive (0.17%). In addition, 537 patients participated in the second online survey, with 467 patients having COVID-19 infection (86.96%). (1) During zero-COVID, all of the COVID-19-positive patients had mild symptoms of COVID-19 and no death was reported. After zero-COVID, 83.51% of the COVID-19-positive patients had mild symptoms. The overall death rate and inpatient mortality rate of COVID-19-positive PD patients were 3.21% and 30.00%, respectively. (2) During zero-COVID, 49.43% of PD patients reported worsening of PD-related symptoms (lockdown vs. unlockdown, 60.50% vs. 48.02%, P = 0.0009). After zero-COVID, 54.93% of PD patients reported worsening of PD-related symptoms (COVID-19 positive vs. COVID-19 negative, 59.31% vs. 25.71%, P < 0.0001). (3) During zero-COVID, 62.36% of patients felt worried, and 'limited outdoor activities' (55.39%) was the top reason for mental health problems. After zero-COVID, 59.03% of patients felt worried, with 'poor health' (58.10%) being the top reason. The PD patients tended to change their daily activities from offline to online, and their economic and caregiver burdens increased both during and after zero-COVID. (4) Most PD patients would like to choose online rehabilitation during (69.56%) and after zero-COVID (69.27%). The demand for online medication purchasing also increased during (47.00%) and after zero-COVID (26.63%).

CONCLUSIONS:

The COVID-19 pandemic aggravated the motor and non-motor symptoms of PD patients either during or after the zero-COVID policy period. The PD patients also experienced prominent mental health problems, changes in daily activities, and increases in economic and caregiver burdens. The COVID-19 pandemic has changed ways of PD management with increasing demands for online medication purchasing and rehabilitation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / COVID-19 Tipo de estudio: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Transl Neurodegener Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / COVID-19 Tipo de estudio: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Transl Neurodegener Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido